-
公开(公告)号：US20050267222A1
公开(公告)日：2005-12-01
申请号：US10531915
申请日：2003-10-21
CPC分类号： A61K9/2018 , A61K9/2013 , A61K9/2054 , A61K9/2095
摘要： The present invention provides a composition containing a substance being capable of supplying aldehyde-like substances to be used in the field of medicaments, cosmetics, hair care products, etc., that contains a low-molecular weight active substance the stability of which is impaired by the effects of aldehydes and a stabilizer having an amine structure and being capable of absorbing aldehydes, and has an improved stability to aldehyde of said low-molecular weight active the stability of which is impaired by the effects of aldehydes substance; and a method for stabilizing such a low-molecular weight active substance. An example of said stabilizer is an aminosugar or a polymer thereof, an aminosugar alcohol or a polymer thereof, an amino acid or a polymer thereof, a protein or a hydrolysate thereof, an alkylamine, a hydroxyalkylamine, or a salt thereof.
摘要翻译： 本发明提供一种含有能够供给用于药物，化妆品，护发产品等领域的醛类物质的物质的组合物，其含有稳定性受损的低分子量活性物质 通过醛和具有胺结构并且能够吸收醛的稳定剂的作用，并且对于所述低分子量活性物的醛的稳定性具有改善的稳定性，其稳定性受到醛类物质的影响; 和稳定这种低分子量活性物质的方法。 所述稳定剂的实例是氨基糖或其聚合物，氨基糖醇或其聚合物，氨基酸或其聚合物，蛋白质或其水解产物，烷基胺，羟烷基胺或其盐。
-
公开(公告)号：US20090028939A1
公开(公告)日：2009-01-29
申请号：US12086700
申请日：2006-12-21
IPC分类号： A61K9/14 , A61K31/4439 , A61K9/20 , A61P3/00
CPC分类号： A61K9/209 , A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K31/366 , A61K31/4439 , A61K31/64
摘要： The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.
摘要翻译： 本发明提供一种固体制剂，其含有胰岛素敏化剂和胰岛素敏化剂以外的活性成分，并且表现出胰岛素敏化剂与胰岛素敏化剂类似的胰岛素敏化剂的溶解行为，其来自“仅含胰岛素敏化剂的固体制剂如 活性成分“。 固体制剂包括“含有包含胰岛素敏化剂的颗粒的包衣颗粒的部分用乳糖或糖醇包衣的部分”和“含有胰岛素敏化剂以外的活性成分的部分”。
-
公开(公告)号：US09427434B2
公开(公告)日：2016-08-30
申请号：US12452587
申请日：2008-07-10
IPC分类号： A61K31/4439 , A61K9/16 , A61K9/50 , A61K9/20
CPC分类号： A61K31/4439 , A61K9/1676 , A61K9/2095 , A61K9/5078
摘要： The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.
摘要翻译： 本发明提供含有吡格列酮或其盐作为活性成分的制剂，其显示出吡格列酮的高生物利用度和血药浓度的个体差异较小，以及在保存期间具有抑制的颜色变化的制剂。 该制剂包含含有不低于10mg / mL的20℃水溶性的药学上可接受的有机酸的核心和25℃下的pKa1（第一种酸解离常数Ka1的负常数对数）不超过 以及含有吡格列酮或其盐的涂层。 涂层还可以含有甘露醇或海藻糖。
-
公开(公告)号：US20100166853A1
公开(公告)日：2010-07-01
申请号：US12452587
申请日：2008-07-10
IPC分类号： A61K9/64 , A61K31/4439
CPC分类号： A61K31/4439 , A61K9/1676 , A61K9/2095 , A61K9/5078
摘要： The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.
摘要翻译： 本发明提供含有吡格列酮或其盐作为活性成分的制剂，其显示出吡格列酮的高生物利用度和血药浓度的个体差异较小，以及在保存期间具有抑制的颜色变化的制剂。 该制剂包含含有不低于10mg / mL的20℃水溶性的药学上可接受的有机酸的核心和25℃下的pKa1（第一种酸解离常数Ka1的负常数对数）不超过 以及含有吡格列酮或其盐的涂层。 涂层还可以含有甘露醇或海藻糖。
-
5.发明授权
公开(公告)号：US5629316A
公开(公告)日：1997-05-13
申请号：US266641
申请日：1994-06-28
CPC分类号： A61K47/22 , A61K31/52 , A61K9/1617 , A61K9/2013 , Y10S514/849
摘要： To stabilize the active ingredients, a caffeine is incorporated into a solid pharmaceutical preparation comprising a dextromethorphan and a phenylpropanolamine. The pharmaceutical preparation may further comprise ibuprofen. The active ingredients may be further stabilized, in combination with the incorporation of the caffeine, by grouping and incorporating separately each or suitably combined plural of the active ingredients into different groups or by minimizing the amount of any reducing sugar such as lactose. The solid pharmaceutical preparation is practically valuable since decomposition of each active ingredient with the lapse of time is remarkably suppressed and the active ingredients are stabilized for a longer period of time.
摘要翻译： 为了稳定活性成分，将咖啡因加入到包含右美沙芬和苯丙醇胺的固体药物制剂中。 药物制剂还可以包含布洛芬。 活性成分可以进一步与咖啡因的掺入相结合，通过将各个或适当组合的多种活性成分分开并合并成不同的组，或通过最小化任何还原糖例如乳糖的量来进一步稳定。 固体药物制剂实际上是有价值的，因为随着时间的流逝，各活性成分的分解被显着抑制，活性成分稳定了较长的时间。
-
公开(公告)号：US08071130B2
公开(公告)日：2011-12-06
申请号：US12086700
申请日：2006-12-21
CPC分类号： A61K9/209 , A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K31/366 , A61K31/4439 , A61K31/64
摘要： The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.
摘要翻译： 本发明提供一种固体制剂，其含有胰岛素敏化剂和胰岛素敏化剂以外的活性成分，并且表现出胰岛素敏化剂与胰岛素敏化剂类似的胰岛素敏化剂的溶解行为，其来自“仅含胰岛素敏化剂的固体制剂如 活性成分“。 固体制剂包括“含有包含胰岛素敏化剂的颗粒的包衣颗粒的部分用乳糖或糖醇包衣的部分”和“含有胰岛素敏化剂以外的活性成分的部分”。
-
公开(公告)号：US08637079B2
公开(公告)日：2014-01-28
申请号：US12449255
申请日：2008-01-30
CPC分类号： A61K9/209 , A61K31/4439 , A61K31/4545 , A61K2300/00
摘要： A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
摘要翻译： 包含化合物（I）的固体制剂，其中化合物（I）的定义如说明书中所定义，吡格列酮可用作糖尿病等的治疗药物，并且溶解性，化学稳定性和溶解性优异 提供稳定性。 含有以下第一和第二部分的固体制剂：（1）含有化合物（I）的第一部分或其盐，作为第一赋形剂的糖或糖醇; 和（2）含有吡格列酮或其盐的第二部分和作为第二赋形剂的糖或糖醇。
-
公开(公告)号：US20100092551A1
公开(公告)日：2010-04-15
申请号：US12449255
申请日：2008-01-30
IPC分类号： A61K9/28 , A61K31/506 , A61P3/10
CPC分类号： A61K9/209 , A61K31/4439 , A61K31/4545 , A61K2300/00
摘要： A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
摘要翻译： 包含化合物（I）的固体制剂，其中化合物（I）的定义如说明书中所定义，吡格列酮可用作糖尿病等的治疗药物，并且溶解性，化学稳定性和溶解性优异 提供稳定性。 含有以下第一和第二部分的固体制剂：（1）含有化合物（I）的第一部分或其盐，作为第一赋形剂的糖或糖醇; 和（2）含有吡格列酮或其盐的第二部分和作为第二赋形剂的糖或糖醇。
-
9.发明授权
公开(公告)号：US5726180A
公开(公告)日：1998-03-10
申请号：US742179
申请日：1996-10-30
CPC分类号： A61K47/22 , A61K31/52 , A61K9/1617 , A61K9/2013 , Y10S514/849
摘要： To stabilize the active ingredients, a caffeine is incorporated into a solid pharmaceutical preparation comprising a dextromethorphan and a phenylpropanolamine. The pharmaceutical preparation may further comprise ibuprofen. The active ingredients may be further stabilized, in combination with the incorporation of the caffeine, by grouping and incorporating separately each or suitably combined plural of the active ingredients into different groups or by minimizing the amount of any reducing sugar such as lactose. The solid pharmaceutical preparation is practically valuable since decomposition of each active ingredient with the lapse of time is remarkably suppressed and the active ingredients are stabilized for a longer period of time.
摘要翻译： 为了稳定活性成分，将咖啡因加入到包含右美沙芬和苯丙醇胺的固体药物制剂中。 药物制剂还可以包含布洛芬。 活性成分可以进一步与咖啡因的掺入相结合，通过将各个或适当组合的多种活性成分分开并合并成不同的组，或通过最小化任何还原糖例如乳糖的量来进一步稳定。 固体药物制剂实际上是有价值的，因为随着时间的流逝，各活性成分的分解被显着抑制，活性成分稳定了较长的时间。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.021 秒)